NCT00995410View on ClinicalTrials.gov

Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers

PHASE3CompletedINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions

Aspirin-Associated Gastric Ulcers

Interventions

DRUG

PA32540

PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily

Trial Locations (1)

27519

Pozen, Chapel Hill

Sponsors

Lead Sponsor

All Listed Sponsors

lead

POZEN

INDUSTRY